Evidence map›Paper›PMID 39553019›Full record

ArticleCureus2024

Use of Mesenchymal Stem Cell Transplantation as a Treatment for Liver Cirrhosis in Animal Models.

Alexander G Skuratov, Boris B Osipov, Anatoly N Lyzikov, Dmitry A Zinovkin, Imran M Adam, Mark L Kaplan, Anton A Prisentsov, Evgeny V Voropaev, Madusha M P Angage

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexander G SkuratovDepartment of Surgical Diseases No1 with the Course of Cardiovascular Surgery, Gomel State Medical University, Gomel, BLR.
Boris B OsipovDepartment of Surgical Diseases No1 with the Course of Cardiovascular Surgery, Gomel State Medical University, Gomel, BLR.
Anatoly N LyzikovDepartment of Surgical Diseases No1 with the Course of Cardiovascular Surgery, Gomel State Medical University, Gomel, BLR.
Dmitry A ZinovkinDepartment of Pathology, Gomel State Medical University, Gomel, BLR.
Imran M AdamDepartment of Surgical Diseases No1 with the Course of Cardiovascular Surgery, Gomel State Medical University, Gomel, BLR.
Mark L KaplanDepartment of Surgical Diseases No1 with the Course of Cardiovascular Surgery, Gomel State Medical University, Gomel, BLR.
Anton A PrisentsovDepartment of Surgical Diseases No1 with the Course of Cardiovascular Surgery, Gomel State Medical University, Gomel, BLR.
Evgeny V VoropaevDepartment of Research, Gomel State Medical University, Gomel, BLR.
Madusha M P AngageDepartment of Surgical Diseases No1 with the Course of Cardiovascular Surgery, Gomel State Medical University, Gomel, BLR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionLiver cirrhosis is one of the top 10 causes of death worldwide, and liver disease is in the top five in many developing countries. The treatment of liver cirrhosis at various stages necessitates the development of new organ transplantation techniques. One of these options is cell therapy, which has lately been used to treat a wide range of illnesses.

methodsThe study used a rabbit model of liver cirrhosis to examine the efficiency of mesenchymal stem cell (MSC) transplantation. Subcutaneous injections of carbon tetrachloride (CCL4) were used to cause liver cirrhosis. When liver cirrhosis developed, autologous mesenchymal stem cells were infused into the portal vein.

resultsThe histological image of the cirrhotic liver improved one month after MSC transplantation.

conclusionThis demonstrates that the intraportal delivery of autologous MSC to rabbits with experimental liver cirrhosis has good therapeutic outcomes.

Indexed as

experimental animal studyliver cirrhosis. fibrosismesenchymal stem cells (mscs)stem cell therapy effectivenesstreatment methods

Identifiers

PMID39553019
PMCPMC11568846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.